Long-term Real-world Study of Dupilumab in COPD : Patient Characteristics, Safety and Patient-reported Outcomes
← catalyst calendarNCT07380711 · readout in 1,456 d
Sponsored by Sanofi (industry) · SNY — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
500estimated
Sites
22
Country
France
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-01-28 | actual | When the study began enrolling |
| Primary completion | 2030-08-14 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2030-08-14 | estimated | The whole study's end, after follow-up |
| First posted | 2026-02-02 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-14 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Chronic Obstructive Pulmonary Disease COPD
Primary outcomes
what the primary-completion date above is the date OFDescriptive statistical analysis of socio-demographics
measured Baseline
Descriptive statistical analysis of medical disease
measured Baseline
Descriptive statistical analysis of treatment history
measured Baseline
Descriptive statistical analysis of clinical disease characteristics (symptoms)
measured In the 1 year prior to Dupilumab initiation
Descriptive statistical analysis of clinical disease characteristics (exacerbations)
measured In the 2 years prior to Dupilumab initiation
Descriptive statistical analysis of clinical disease characteristics (lung function parameters)
measured In the 1 year prior to Dupilumab initiation
Descriptive statistical analysis of clinical disease characteristics (max eosinophils [EOS])
measured In the 1 year prior to Dupilumab initiation
Descriptive statistical analysis of clinical disease characteristics (fractional exhaled nitric oxide [FeNO] levels)
measured In the 1 year prior to Dupilumab initiation
Descriptive statistical analysis of clinical disease characteristics (immunoglobulin E [IgE] levels)
measured In the 1 year prior to Dupilumab initiation
Descriptive statistical analysis of clinical disease characteristics (Global Initiative for Chronic Obstructive Lung Disease (GOLD) grade and group)
measured Baseline
Descriptive statistical analysis of clinical disease characteristics (smoking status and pack years (tobacco and cannabis))
measured Baseline
Descriptive statistical analysis of clinical disease characteristics (treated asthma in childhood and concomitant asthma according to the investigator opinion)
measured Baseline
Descriptive statistical analysis of clinical disease characteristics (Cardiovascular (CV) comorbidities)
measured Baseline
Descriptive statistical analysis of clinical disease characteristics (Otorhinolaryngology (ORL) comorbidities)
measured Baseline
Descriptive statistical analysis of clinical disease characteristics (date of Chronic Obstructive Pulmonary Disease (COPD) diagnosis)
measured Baseline
Date of COPD diagnosis and GOLD grade/group at COPD diagnosis
measured Baseline
Descriptive statistical analysis of clinical disease characteristics (BODE and/or BODEx scores-index for COPD survival)
measured Baseline
Descriptive statistical analysis of clinical disease characteristics (history of pulmonary rehabilitation)
measured Baseline
Descriptive statistical analysis of Hospital Anxiety and Depression scale (HADS).
measured Baseline
Descriptive statistical analysis of Vaccine status.
measured Baseline
Descriptive statistical analysis of Emphysema assessment according to treating physician, based on CT scan
measured In the last 3 years prior to treatment initiation
Permalink · SNY's whole pipeline · Catalyst calendar · Every registered study · What changed